Trials / Completed
CompletedNCT00124527
Study of Irofulven Plus Capecitabine in Patients With Advanced Thyroid Cancer
Phase 2 Clinical Trial of Bi-weekly Dosing of Irofulven Plus Capecitabine in Patients With Anaplastic or Locally Advanced/Metastatic Differentiated Thyroid Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 35 (planned)
- Sponsor
- Eisai Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Irofulven is an investigational chemotherapeutic agent being studied in a variety of solid tumors. The purpose of this study is to assess the efficacy and safety of irofulven/capecitabine combination therapy in patients with anaplastic, medullary, or locally advanced/metastatic differentiated thyroid cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Irofulven + capecitabine |
Timeline
- Start date
- 2005-03-31
- Primary completion
- 2006-08-31
- Completion
- 2006-08-31
- First posted
- 2005-07-28
- Last updated
- 2021-06-16
Locations
10 sites across 6 countries: United States, Argentina, France, Peru, Russia, Ukraine
Source: ClinicalTrials.gov record NCT00124527. Inclusion in this directory is not an endorsement.